Doris M Ponce Selected Research

Doris M Ponce Research Topics

Disease

20	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2023 - 01/2015
9	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 09/2011
7	Leukemia 12/2023 - 05/2013
5	Infections 12/2023 - 06/2014
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2021 - 12/2015
3	Neoplasms (Cancer) 05/2023 - 11/2021
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2021 - 01/2017
2	Cytopenia 01/2023 - 11/2021
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2022 - 11/2015
2	COVID-19 01/2022 - 01/2021
2	Bronchiolitis Obliterans Syndrome 11/2021 - 03/2017
1	Agammaglobulinemia (Hypogammaglobulinemia) 12/2023
1	Primary Myelofibrosis (Myelosclerosis) 01/2022
1	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2022
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2021
1	Death (Near-Death Experience) 12/2020
1	Skin Diseases (Skin Disease) 12/2019
1	Diphtheria 12/2015
1	Tetanus 12/2015
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2015
1	Whooping Cough (Pertussis) 12/2015
1	Rubella (German Measles) 12/2015
1	Poliomyelitis (Polio) 12/2015
1	Measles 12/2015
1	Mumps 12/2015
1	Vaccine-Preventable Diseases 12/2015
1	Viremia 06/2014
1	Encephalitis (Encephalitis, Rasmussen) 06/2014

Drug/Important Bio-Agent (IBA)

3	Calcineurin InhibitorsIBA 01/2022 - 06/2014
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 05/2015 - 05/2013
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2023 - 05/2013
2	Biomarkers (Surrogate Marker)IBA 05/2023 - 10/2021
2	AntibodiesIBA 01/2022 - 05/2014
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 12/2020
2	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 12/2015 - 06/2014
1	letermovirIBA 12/2023
1	DNA (Deoxyribonucleic Acid)IBA 12/2023
1	terminaseIBA 12/2023
1	Natalizumab (Tysabri)FDA Link 12/2023
1	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2023
1	ElectrolytesIBA 01/2023
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2022
1	cilgavimabIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Heparin (Liquaemin)FDA LinkGeneric 01/2022
1	tixagevimabIBA 01/2022
1	cilgavimab and tixagevimab drug combinationIBA 01/2022
1	venetoclaxIBA 12/2021
1	Transaminases (Aminotransferases)IBA 11/2021
1	CytokinesIBA 11/2021
1	Proteasome InhibitorsIBA 11/2021
1	ixazomibIBA 11/2021
1	Chimeric Antigen ReceptorsIBA 01/2021
1	VaccinesIBA 12/2015
1	Rituximab (Mabthera)FDA Link 12/2015
1	Pyridinolcarbamate (P23)IBA 12/2015
1	Tacrolimus (Prograf)FDA LinkGeneric 03/2015
1	Methotrexate (Mexate)FDA LinkGeneric 03/2015
1	Sirolimus (Rapamycin)FDA Link 03/2015
1	Dextrans (Dextran)FDA Link 04/2014
1	AlbuminsIBA 04/2014
1	fludarabineIBA 05/2013
1	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 05/2013
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 05/2013
1	alpha-isobutyl-4-hydroxybenzyl alcohol (T 108)IBA 09/2011

Therapy/Procedure

15	Transplantation 01/2023 - 09/2011
14	Cell Transplantation 12/2023 - 01/2017
10	Therapeutics 12/2023 - 06/2014
6	Hematopoietic Stem Cell Transplantation 01/2022 - 12/2015
4	Stem Cell Transplantation 01/2022 - 01/2021
1	Salvage Therapy 12/2021
1	Treatment Delay 01/2021